Vorolanib is a small molecule commercialized by EyePoint Pharmaceuticals, with a leading Phase II program in Non-Proliferative Diabetic Retinopathy (NPDR). According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Vorolanib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Vorolanib is expected to reach an annual total of $287 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vorolanib Overview
Vorolanib is under development for the treatment of wet age-related macular degeneration and nonproliferative diabetic retinopathy (NPDR) diabetic macular edema and pathological myopia choroidal neovascularization (pmCNV). The drug candidate is a combination of a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib. It is administered through intravitreal route. The drug candidate acts by targeting VEGF. The therapeutic candidate is developed based on Durasert technology and delivered using Medidur to provide sustained release. Medidur is a miniaturized, injectable, sustained-release drug delivery system. It was also under development for the treatment of dry age-related macular degeneration, retinal vein occlusion.
.
EyePoint Pharmaceuticals Overview
EyePoint Pharmaceuticals (EyePoint), formerly pSivida, is a pharmaceutical company that develops and commercializes therapies for treatment of eye disorders. The company utilizes its Duraset platform, a miniaturized, injectable, and sustained delivery system to develop its product. Its pipeline products includes EYP-1901, an investigational sustained delivery intravital anti-VEGF treatment that targets wet age-related macular degeneration (Wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macularedema (DME). The company also markets its product such as Yutiq, a fluocinolone acetonide intravitreal implant to treat chronic non-infectious uvetis; and Dexycu for treatment of postoperative inflammation. EyePoint is headquartered in Watertown, Massachusetts, the US.
For a complete picture of Vorolanib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
